Key result
Drug-coated balloons provide clinically significant benefits in managing in-stent restenosis, diffuse coronary artery disease, and small coronary artery lesions compared to drug-eluting stents.
Why the study?
Current DES fails to show non-inferiority to CABG for cumulative clinical events and has higher target vessel revascularization risks, warranting exploration of DCB advantages for long-term outcomes.
Do drug-coated balloons improve long-term outcomes compared to drug-eluting stents or CABG in patients with coronary artery disease?
Do drug-coated balloons improve long-term outcomes compared to drug-eluting stents or CABG in patients with coronary artery disease?
Drug-coated balloons may offer long-term benefits over drug-eluting stents and potentially match CABG performance in complex coronary artery disease.
Answers are grounded in this paper and cite their sources.
May support drug-coated balloon use in select lesions; leaves open randomized trials on long-term outcomes versus stents or CABG.
Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) represents the treatment of choice for the majority of patients with coronary artery disease. While currently available DES, in addition to physiological support, has failed to show the non-inferiority to coronary artery bypass grafting (CABG) in terms of cumulative incidence of clinical events over the short-term follow-up. Studies have also shown that DES is associated with an increased risk of target vessel revascularization compared to CABG after long-term follow-up. Drug-coated balloons (DCB) have been shown to provide clinically significant benefits in the management of in-stent restenosis and diffuse coronary artery disease, as well as small coronary artery lesions. The aim of this review was to describe the inherent technical limitations of DES and highlight the potential advantages of PCI with DCB for long-term outcomes and potentially demonstrate its non-inferiority to CABG. Currently, ongoing studies will provide more information and help to understand if a blended therapy of DCB+DES can match the performance of CABG in the need for revascularization in more complex patients.
No takes yet. Share an insight, caveat, or question.
Cortese et al. (2023) conducted a review in Coronary artery disease. Drug-coated balloons (DCB) vs. Drug-eluting stents (DES) and Coronary artery bypass grafting (CABG) was evaluated. Drug-coated balloons provide clinically significant benefits in managing in-stent restenosis, diffuse coronary artery disease, and small coronary artery lesions compared to drug-eluting stents.
Synapse has enriched 10 related papers. Consider them for comparative context: